Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5467690 | 0.95 | IDO1 (0.47) | IDO1SIGMAR1CYP19A1TBXAS1BLM | |
| SCHEMBL833049 | 0.88 | HTR6 (0.50) | HTR6IDO1 | |
| SCHEMBL3246802 | 0.79 | FFAR1 (0.51) | BLMTSHR | |
| SCHEMBL5613177 | 0.78 | HTR1A (0.49) | IDO1SIGMAR1CYP19A1TBXAS1 | |
| SCHEMBL428148 | 0.77 | HTR2A (0.53) | HTR6IDO1SIGMAR1 | |
| SCHEMBL15320085 | 0.77 | HTR6 (0.46) | HTR6IDO1SIGMAR1CYP19A1TBXAS1 | |
| SCHEMBL11574737 | 0.77 | IDO1 (0.47) | HTR6IDO1SIGMAR1CYP19A1TBXAS1 | |
| Ethoxycarbonyl Group SCHEMBL28770651 | 0.76 | HTR6 (0.40) | HTR6IDO1SIGMAR1 | |
| SCHEMBL1566770 | 0.75 | CYP19A1 (0.49) | IDO1SIGMAR1CYP19A1TBXAS1BLM | |
| SCHEMBL11948317 | 0.75 | SIGMAR1 (0.47) | SIGMAR1CYP19A1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2189443-B1 | TRICYCLIC AMIDE COMPOUND | RES FOUND ITSUU LAB (JP) | 2013-10-23 | — | — | EP | disclosed |
| EP-2189443-B1 | TRICYCLIC AMIDE COMPOUND | RES FOUND ITSUU LAB (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-8232300-B2 | Tricyclic amide compound | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2012-07-31 | — | — | US | disclosed |
| US-8232300-B2 | Tricyclic amide compound | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2012-07-31 | — | — | US | disclosed |
| US-8143260-B2 | Tricyclic amine compound | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20110288299-A1 | TRICYCLIC AMINE COMPOUND | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2011-11-24 | — | — | US | disclosed |
| US-20110213157-A1 | TRICYCLIC AMIDE COMPOUND | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110213157-A1 | TRICYCLIC AMIDE COMPOUND | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2189440-A1 | TRICYCLIC AMINE COMPOUND | Research Foundation Itsuu Laboratory (JP) | 2010-05-26 | — | — | EP | disclosed |
| EP-2189443-A1 | TRICYCLIC AMIDE COMPOUND | Research Foundation Itsuu Laboratory (JP) | 2010-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213157-A1 | TRICYCLIC AMIDE COMPOUND | RXRA, RXRB, RXRG | HTR6 815/4885IDO1 2555/4885SIGMAR1 116/4885 |
| US-20110288299-A1 | TRICYCLIC AMINE COMPOUND | RXRA, RXRB, NR2C2 | HTR6 240/4885IDO1 2197/4885SIGMAR1 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.